Wonder what a big cheese in Big Pharma earn these days? Well, Wyeth told the Securities & Exchange Commission that it plans to pay its new chief Bernard Poussot (photo [1]) $1.5 million in base salary, plus 120,000 restricted stock units that start vesting in three years. Meanwhile, its non-employee directors will get $220,000 annually in 2008 and 2009.
Remember, though, that base pay is just that. According to Forbes, Wyeth's current CEO, Robert Essner, raked in $25.66 million in 2006, including base pay, bonuses, stock, and perks.
- read the AP report [2]
- see the figures [3] on Essner in Forbes
Related Articles:
Wyeth names Poussot CEO. Report [4]
Wyeth stock down after several setbacks. Report [5]
Wyeth CEO: FDA creating monopoly meds. Report [6]
Links:
[1] http://www.fiercebiotech.com/pages/wyeth-ceo-bernard-poussot
[2] http://biz.yahoo.com/ap/071120/wyeth_compensation.html?.v=1
[3] http://www.forbes.com/lists/2007/12/lead_07ceos_CEO-Compensation-Drugs-biotechnology_9Rank.html
[4] http://www.fiercebiotech.com/story/wyeth-names-poussot-ceo/2007-09-28
[5] http://www.fiercepharma.com/story/wyeth-stock-down-after-several-setbacks/2007-08-13
[6] http://www.fiercepharma.com/story/wyeth-ceo-fda-creating-monopoly-meds/2007-11-05